- Home
- VCEL vs CMMB Comparison
VCEL vs CMMB Comparison
Compare VCEL & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCEL
- CMMB
- Stock Information
- Founded
- VCEL 1989
- CMMB 2004
- Country
- VCEL United States
- CMMB Israel
- Employees
- VCEL N/A
- CMMB N/A
- Industry
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- VCEL Health Care
- CMMB Health Care
- Exchange
- VCEL Nasdaq
- CMMB Nasdaq
- Market Cap
- VCEL 2.1B
- CMMB 22.0M
- IPO Year
- VCEL 1997
- CMMB N/A
- Fundamental
- Price
- VCEL $32.18
- CMMB $3.03
- Analyst Decision
- VCEL Strong Buy
- CMMB Strong Buy
- Analyst Count
- VCEL 6
- CMMB 2
- Target Price
- VCEL $61.50
- CMMB $26.50
- AVG Volume (30 Days)
- VCEL 665.7K
- CMMB 143.6K
- Earning Date
- VCEL 11-06-2025
- CMMB 08-14-2025
- Dividend Yield
- VCEL N/A
- CMMB N/A
- EPS Growth
- VCEL 2045.40
- CMMB N/A
- EPS
- VCEL 0.13
- CMMB N/A
- Revenue
- VCEL $249,119,000.00
- CMMB N/A
- Revenue This Year
- VCEL $18.35
- CMMB N/A
- Revenue Next Year
- VCEL $22.47
- CMMB N/A
- P/E Ratio
- VCEL $240.58
- CMMB N/A
- Revenue Growth
- VCEL 16.13
- CMMB N/A
- 52 Week Low
- VCEL $30.26
- CMMB $2.96
- 52 Week High
- VCEL $63.00
- CMMB $9.84
- Technical
- Relative Strength Index (RSI)
- VCEL 38.67
- CMMB 26.72
- Support Level
- VCEL $30.26
- CMMB $2.96
- Resistance Level
- VCEL $33.92
- CMMB $3.14
- Average True Range (ATR)
- VCEL 1.53
- CMMB 0.22
- MACD
- VCEL -0.19
- CMMB 0.01
- Stochastic Oscillator
- VCEL 27.79
- CMMB 8.09
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.